[PDF][PDF] Neurotheranostics as personalized medicines
Bhavesh D. Kevadiya a, Brendan M. Ottemann a, Midhun Ben Thomas a, Insiya Mukadam b,
Saumya Nigam a, JoEllyn McMillan a, Santhi Gorantla a, Tatiana K. Bronich b, Benson …
Saumya Nigam a, JoEllyn McMillan a, Santhi Gorantla a, Tatiana K. Bronich b, Benson …
[HTML][HTML] Neurotheranostics as personalized medicines
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic
clinical outcomes for neurological disorders. Research was facilitated, in largest measure …
clinical outcomes for neurological disorders. Research was facilitated, in largest measure …
Neurotherapeutics: Concept, Translation, Transition
AI Faden - Neurotherapeutics, 2014 - Springer
The mission of ASENT is to facilitate the clinical translation of basic neuroscience
discoveries to improve the treatment of neurological and psychiatric disorders. When …
discoveries to improve the treatment of neurological and psychiatric disorders. When …
Nanotheranostics: the future remedy of neurological disorders
S Sohail - Cancer Nanotheranostics: Volume 2, 2021 - Springer
Informative Abstract Clinical results were not improved by therapies aimed at the central
nervous system. Because drugs cannot pass across the blood-brain barrier, the most …
nervous system. Because drugs cannot pass across the blood-brain barrier, the most …
Neurotherapeutics [electronic resource]: Emerging Strategies
LM Pullan, J Patel - sidalc.net
Neuroscience's inherent complexity and rapid growth mean that no one can keep abreast of
all the changes across the field. We each bring a necessarily narrow perspective …
all the changes across the field. We each bring a necessarily narrow perspective …
Handbook of Contemporary Neuropharmacology. Three Volume Set. 2007. Edited by David R. Sibley, Israel Hanin, Michael Kuhar, Phil Skolnick. Published by John …
S Roth - Canadian Journal of Neurological Sciences, 2008 - cambridge.org
During the past few decades, the disciplines of neuroscience and neuropharmacology have
advanced dramatically. This has contributed to a better understanding of the functions of the …
advanced dramatically. This has contributed to a better understanding of the functions of the …
[HTML][HTML] Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
SJ Wang, A Fotenos, SC Masters, L Marzella - Theranostics, 2022 - ncbi.nlm.nih.gov
Background Diagnosis and therapy share a nuanced relationship in medicine. While most
patients experience diagnosis prior to therapy in temporal sequence, causal linkages …
patients experience diagnosis prior to therapy in temporal sequence, causal linkages …
Phase 3 NEURO-TTRansform Findings Signify Eplontersen as Promising Agent for hATTR Polyneuropathy.
M Meglio - Neurology Live, 2023 - go.gale.com
About a month after Ionis Pharmaceuticals announced positive results from its phase 3
NEURO-TTRansform study (NCT04136184) assessing its investigational agent eplontersen …
NEURO-TTRansform study (NCT04136184) assessing its investigational agent eplontersen …
Nanotheranostics, a future remedy of neurological disorders
Introduction: Effective therapy of various neurological disorders is hindered on account of
the failure of various therapeutics crossing blood-brain-barrier (BBB). Nanotheranostics has …
the failure of various therapeutics crossing blood-brain-barrier (BBB). Nanotheranostics has …
Changing Times at CNS Neuroscience & Therapeutics: Formerly CNS Drug Reviews http://www. blackwellpublishing. com/CNSNT
MH Pollack - CNS Neuroscience & Therapeutics, 2008 - ncbi.nlm.nih.gov
It is an honor, privilege and indeed, challenge to take over as Editor of CNS Neuroscience
and Therapeutics. Formerly entitled CNS Drug Review, this journal grew under the direction …
and Therapeutics. Formerly entitled CNS Drug Review, this journal grew under the direction …